+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

From
Batten Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Batten Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 60 Pages
  • Global
From
Graves' Orbitopathy- Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Orbitopathy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Androgen Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Androgen Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Phosphoglucomutase (PGM 1) Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Phosphoglucomutase (PGM 1) Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acid Sphingomyelinase Deficiency (ASMD) - Pipeline Insight, 2025 - Product Thumbnail Image

Acid Sphingomyelinase Deficiency (ASMD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Diglyceride Acyltransferase (DGAT) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic M1 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic M1 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Congenital Adrenal Hyperplasia- Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Adrenal Hyperplasia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Propionic Acidemia - Pipeline Insight, 2025 - Product Thumbnail Image

Propionic Acidemia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
GM2 Gangliosidosis - Pipeline Insight, 2025 - Product Thumbnail Image

GM2 Gangliosidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Macular Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Macular Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Farber's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Farber's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
GM1 Gangliosidosis - Pipeline Insight, 2025 - Product Thumbnail Image

GM1 Gangliosidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Acute Gout Flare - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Gout Flare - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more